Antibody targeting of the TNF–TNFR2 axis to overcome tumor immune resistance - Takeaways - MDSpire

Antibody targeting of the TNF–TNFR2 axis to overcome tumor immune resistance

  • By

  • Xiaozhen Kang

  • Xiangmin Tong

  • Shibing Wang

  • May 14, 2026

Share

  • 1

    TNFR2 primarily regulates tumor-enhancing inflammation and immunosuppression, contributing to immune evasion in the tumor microenvironment.

  • 2

    Targeting the TNF–TNFR2 pathway offers novel therapeutic strategies, including monoclonal antibodies and bispecific antibodies, to combat immune resistance.

  • 3

    TNFR1 induces cytotoxic signaling, while TNFR2 promotes survival and proliferation, highlighting the need for receptor-selective therapeutic approaches.

  • 4

    Challenges for clinical implementation of TNFR2-targeted therapies include on-target toxicity and the need for patient stratification.

  • 5

    Future strategies may involve biomarker-guided therapy and localized targeting to enhance the efficacy of TNFR2-focused treatments.

Original Source(s)

Antibody targeting of the TNF–TNFR2 axis to overcome tumor immune resistance

  • by Xiaozhen Kang, Xiangmin Tong, Shibing Wang

  • May 14, 2026

Related Content

LLM-Based Preoperative Patient Communications Alleviate Anxiety, Physician Workload

Researchers from the Department of Urology at Fudan University Shanghai Cancer Center evaluated artificial intelligence (AI)–assisted communications in the preoperative setting to assess its impact on...

Global Review Shows Impact of Exposure to Air Pollution on Cancer Risk and Mortality

A new report released by the Union for International Cancer Control shows that people exposed over the long term to fine particulate matter (PM2.5) (such as vehicle exhaust, wildfires, wood burning) h...

Mass Spec Roundup: Proteins, Lipids, Pitcher Plants, and Coffee

This week’s roundup explores hidden chemistry in the dark proteome, forest soils, lipid binding in cells, and pitcher plant food webs

  • May 13, 2026

  • 7 min